Nemaura Medical Inc. (NMRD)

The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.

Nemaura Medical, Inc. (NMRD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LOUGHBOROUGH, England--( BUSINESS WIRE )--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

LOUGHBOROUGH, England--( BUSINESS WIRE )--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The Continuous Glucose Monitoring Market is expanding to consumer-centered CGM wellness devices, targeting Type-2 diabetics, prediabetics, and healthy consumers.

The stock price of Nemaura Medical, Inc. (NASDAQ: NMRD) increased by over 4% today. This is why it happened.

Nemaura is an intriguing company developing a wearable patch for monitoring of glucose & blood sugar levels by Type-2 and pre-diabetes patients.

For millions of diabetic patients worldwide, the reality of constantly having needles pricked into the body for glucose monitoring can be a never-ending nightmare. With over 460 million people current...